tradingkey.logo

Nektar’s Rezolve-AA Trial Meets Target With 28.2% Salt Drop

ReutersDec 16, 2025 1:37 PM

- Nektar Therapeutics NKTR.O:

  • NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY ACHIEVED TARGET PRODUCT PROFILE WITH 28.2% SALT SCORE REDUCTION

  • NEKTAR THERAPEUTICS - REZPEGALDESLEUKIN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE

  • NEKTAR THERAPEUTICS - REZOLVE-AA PHASE 2B STUDY RESULTS SUPPORTS ADVANCEMENT TO PHASE 3 DEVELOPMENT IN ALOPECIA AREATA

  • NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI